Your browser doesn't support javascript.
loading
Disease course after the first recurrence of head and neck squamous cell carcinoma following (chemo)radiation.
de Ridder, Mischa; de Veij Mestdagh, Pieter D; Elbers, Joris B W; Navran, Arash; Zuur, Charlotte L; Smeele, Ludi E; Al-Mamgani, Abrahim.
Affiliation
  • de Ridder M; Department of Radiation Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
  • de Veij Mestdagh PD; Department of Radiation Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
  • Elbers JBW; Department of Radiation Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
  • Navran A; Department of Radiation Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
  • Zuur CL; Department of Head and Neck Surgery, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Smeele LE; Department of Oral and Maxillofacial Surgery, Academic Medical Center, Amsterdam, The Netherlands.
  • Al-Mamgani A; Department of Head and Neck Surgery, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Eur Arch Otorhinolaryngol ; 277(1): 261-268, 2020 Jan.
Article in En | MEDLINE | ID: mdl-31602525
ABSTRACT

PURPOSE:

Recurrent head and neck squamous cell carcinoma (HNSCC) after chemoradiation is a challenging clinical problem. Salvage surgery (SS) is often extensive and mutilating. Oncological outcomes of SS are relatively well known, but little is published about the course of disease after the first recurrence, especially in patients without salvage possibilities. The aim of this study was to analyze the course of disease in patients with recurrent HNSCC after chemoradiation.

METHODS:

We retrospectively analyzed and descriptively reported the disease course in 198 patients with recurrent HNSCC after chemoradiation in the time period after the first recurrence. We scored any type of event, salvage treatment, systemic treatment and overall survival (OS).

RESULTS:

Of the 198 patients with recurrent HNSCC, salvage surgery was attempted in 104 (53%). SS was more frequently given in patients with recurrent laryngeal cancer, isolated regional failure (p < 0.001) and HPV-positive disease (p = 0.09). The 2-year OS of the whole group was 31% and was significantly different by tumor site, type of failure and SS. HPV-positive disease and salvaged recurrences were significantly predictive for better survival. One third of that salvaged patients was still alive without second recurrence. Median survival in patients that received any palliative systemic treatment without surgery, compared to those were no treatment was given, was 6 and 3 months, respectively (p = 0.006).

CONCLUSIONS:

Main factors influencing the course of disease in recurrent HNSCC are the possibilities for SS and HPV-status. Therefore, SS should always be considered and discussed. In patients without possibilities for SS, overall survival is 3-6 months.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Chemoradiotherapy / Squamous Cell Carcinoma of Head and Neck / Head and Neck Neoplasms / Neoplasm Recurrence, Local Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Year: 2020 Type: Article

Full text: 1 Database: MEDLINE Main subject: Chemoradiotherapy / Squamous Cell Carcinoma of Head and Neck / Head and Neck Neoplasms / Neoplasm Recurrence, Local Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Year: 2020 Type: Article